EGFR and lung adenocarcinoma: These results demonstrate that TLSs can be identified in early-stage EGFR-mutant lung adenocarcinoma, despite the tumor immune microenvironment in EGFR-mutant lung adenocarcinoma often being characterized as an “immune-cold” and “immunosuppressive” phenotype.